BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1449117)

  • 1. Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer.
    Hubbard KP; Pazdur R; Ajani JA; Braud E; Blaustein A; King M; Llenado-Lee M; Winn R; Levin B; Abbruzzese JL
    Am J Clin Oncol; 1992 Dec; 15(6):524-7. PubMed ID: 1449117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paclitaxel and concurrent radiation therapy for locally advanced adenocarcinomas of the pancreas, stomach, and gastroesophageal junction.
    Safran H; Akerman P; Cioffi W; Gaissert H; Joseph P; King T; Hesketh PJ; Wanebo H
    Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):53-7. PubMed ID: 10210540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of patients with upper gastrointestinal carcinomas.
    Ajani JA
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-72-S19-76. PubMed ID: 9427271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas.
    Ajani JA; Ilson DH; Kelsen DP
    Semin Oncol; 1996 Oct; 23(5 Suppl 12):55-8. PubMed ID: 8941411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multi-institutional phase II study of BMS-182248-01 (BR96-doxorubicin conjugate) administered every 21 days in patients with advanced gastric adenocarcinoma.
    Ajani JA; Kelsen DP; Haller D; Hargraves K; Healey D
    Cancer J; 2000; 6(2):78-81. PubMed ID: 11069223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of gemcitabine combined oxaliplatin on advanced pancreatic cancer].
    Shi YX; Xu RH; Jiang WQ; Zhang L; Lin TY; Li YH; Xia ZJ; Luo HY; Han B; Wang F; He YJ; Guan ZZ
    Ai Zheng; 2007 Dec; 26(12):1381-4. PubMed ID: 18076807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
    Gebbia V; Majello E; Testa A; Pezzella G; Giuseppe S; Giotta F; Riccardi F; Fortunato S; Colucci G; Gebbia N
    Cancer; 1996 Sep; 78(6):1300-7. PubMed ID: 8826954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer.
    Dragovich T; Mendelson D; Kurtin S; Richardson K; Von Hoff D; Hoos A
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):759-64. PubMed ID: 16847673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
    Al-Batran SE; Atmaca A; Hegewisch-Becker S; Jaeger D; Hahnfeld S; Rummel MJ; Seipelt G; Rost A; Orth J; Knuth A; Jaeger E
    J Clin Oncol; 2004 Feb; 22(4):658-63. PubMed ID: 14966088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma.
    Lim JY; Cho JY; Oh KJ; Choi SH; Lee SI; Jeung HC
    Chemotherapy; 2009; 55(4):200-6. PubMed ID: 19451710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer.
    Oh SY; Kwon HC; Seo BG; Kim SH; Kim JS; Kim HJ
    Acta Oncol; 2007; 46(3):336-41. PubMed ID: 17450469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CBDCA: phase II evaluation in advanced colorectal carcinoma.
    Pazdur R; Samson MK; Baker LH
    Am J Clin Oncol; 1987 Apr; 10(2):136-8. PubMed ID: 3551576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multiple-center phase II study of biweekly oxaliplatin and tegafur-uracil/leucovorin for chemonaive patients with advanced gastric cancer.
    Chen JS; Rau KM; Chen YY; Huang JS; Yang TS; Lin YC; Liau CT; Lee KD; Su YC; Kao RH
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):819-25. PubMed ID: 18663448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of iproplatin in metastatic breast carcinoma.
    Hortobagyi GN; Frye D; Holmes FA; Hug V; Fraschini G; Buzdar AU
    Cancer Treat Rep; 1987 Dec; 71(12):1193-6. PubMed ID: 3690529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.
    Hochster H; Chachoua A; Speyer J; Escalon J; Zeleniuch-Jacquotte A; Muggia F
    J Clin Oncol; 2003 Jul; 21(14):2703-7. PubMed ID: 12860947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of Taxol in patients with advanced gastric carcinoma.
    Ajani JA; Fairweather J; Dumas P; Patt YZ; Pazdur R; Mansfield PF
    Cancer J Sci Am; 1998; 4(4):269-74. PubMed ID: 9689986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL)--a very effective regimen with good patients' compliance for advanced gastric cancer.
    Cheng AL; Yeh KH; Lin JT; Hsu C; Liu MY
    Anticancer Res; 1998; 18(2B):1267-72. PubMed ID: 9615799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I--II study of the combination of 5-FU, doxorubicin, mitomycin, and semustine (FAMMe) in the treatment of adenocarcinoma of the stomach, gastroesophageal junction, and pancreas.
    Karlin DA; Stroehlein JR; Bennetts RW; Jones RD; Heifetz LJ; Mahal PS
    Cancer Treat Rep; 1982 Aug; 66(8):1613-7. PubMed ID: 7105051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of iproplatin (CHIP) in previously treated advanced breast cancer.
    Meisner DJ; Ginsberg S; Ditch A; Louie A; Newman N; Comis R; Poiesz B
    Am J Clin Oncol; 1989 Apr; 12(2):129-31. PubMed ID: 2705402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I--preliminary phase II trial of iproplatin, a cisplatin analogue.
    Paolozzi FP; Gaver R; Poiesz BJ; Louie A; DiFino S; Comis RL; Newman N; Ginsberg S
    Invest New Drugs; 1988 Sep; 6(3):199-206. PubMed ID: 3192385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.